◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Novartis AG (NOVN) Net Income 2021–2025

Name: Novartis AG (NOVN) net income history 2021-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Novartis AG annual net income for fiscal 2025 was $14.0 billion, an increase of 17.1% from $11.9 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

NOVN Annual Net Income

Net Income (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Net Income	$14.0B	$11.9B	$14.8B	$7.0B	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NOVN Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Net Income	$3.3B	$3.2B	$2.4B	$3.9B	$4.0B	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4568 Net Income — Daiichi Sankyo Company, Limited
4503 Net Income — Astellas Pharma Inc.
4528 Net Income — Ono Pharmaceutical Co., Ltd.
4536 Net Income — Santen Pharmaceutical Co., Ltd.

More NOVN metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All NOVN financial statements → Interactive NOVN charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.